AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06759324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live kombucha (non filtered/ non pasteurized)
Description: Participants receive a daily amount of 33 cl of live kombucha (non-pasteurized/ non-filtered) for 4 weeks (28 days).
Study NCT06759324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized kombucha (non filtered)
Description: Participants receive a daily amount of 33 cl of kombucha (pasteurized drink) for 4 weeks (28 days).
Study NCT06759324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (sparkling water)
Description: Participants receive a daily amount of 33 cl of sparkling water for 4 weeks.
Study NCT04908202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT04908202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05549661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05549661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT05549661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO
Study NCT05549661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound imaging
Study NCT05310136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBTi
Description: On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
Study NCT05278871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constructive Shearwave Interference (CSI)
Description: handheld ultrasound
Study NCT05774951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant. Experimental. Administered orally
Study NCT06293326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bi-layer calcium carbonate tablet (BAY1180654)
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Study NCT05774951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen. Comparator. Administered per local approved label
Study NCT05774951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole. Comparator. Administered per local approved label
Study NCT05774951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole. Comparator. Administered per local approved label
Study NCT05774951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane. Comparator. Administered per local approved label
Study NCT04928248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Dashboard integrated with Disease Manager App
Description: The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
Study NCT04874558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultra-low dose chest CT
Description: A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
Study NCT05844449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study NCT06552624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magaldrate
Description: A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Study NCT06552624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magaldrate
Description: A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Study NCT04725305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiZact
Description: It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
Study NCT04725305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: This method would involve removal of tonsils using electrocautery technique
Study NCT05167877 — intervention group
Intervention type: OTHER
Intervention: No intervention will be given to the participants
Description: This is an observational feasibility study with no intervention.
Study NCT03768310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR-multiVST for Group A
Description: Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
Study NCT03768310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR-multiVST for Group B
Description: Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
Study NCT04970979 — intervention group
Intervention type: OTHER
Intervention: survey
Description: questionnaire about the influencing factors of home-based cardiac rehabilitation
Study NCT05528341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKG2D-CAR-NK92 cells
Description: NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
Study NCT06293326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release calcium carbonate tablet (BAY1180654)
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Study NCT05253222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: retrograde image by colonic TET
Description: Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated.
Study NCT04987255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free visit
Description: The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
Study NCT04987255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided visit
Description: The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
Study NCT04987255 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Guided visit (stroke)
Description: The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
Study NCT05109741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Psychodynamic Therapy
Description: Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
Study NCT05109741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Behavioral Activation
Description: Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
Study NCT05588453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given UD TGFbi NK cell IV
Study NCT05588453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT05817370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Training on screening and treatment of HSIL (e-STH)
Description: Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
Study NCT05190419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
Study NCT05190419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT06513455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome（40mg/m2）
Description: irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
Study NCT06513455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w
Study NCT06513455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
Study NCT06555237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: Trametynib orally once daily in 0,025mg/kg dose
Study NCT06555237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Disopiramide and Beta blockers orally
Study NCT04832919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Community-Family Partnership Intervention
Description: Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
Study NCT05072717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion with Indocyanine green
Description: Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
Study NCT06365671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stem-cell transplantation
Description: high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)
Study NCT06365671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relmacabtagene autoleucel (relma-cel)
Description: relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
Study NCT06254027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forte
Description: One application per day for a complete treatment period.
Study NCT06254027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cover Light
Description: One application per day for a complete treatment period.
Study NCT06254027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl
Description: One application per week for a complete treatment period.
Study NCT06102252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/epirubcin/carboplatin
Description: adjuvant treatment in endometrial carcinoma
Study NCT06102252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/carboplatin
Description: Dose dense paclitaxel/carboplatin
Study NCT04142489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: solar irradiation and biopsies
Description: the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
Study NCT04341623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cetaphil Pro Eczema moisturizer
Description: All 30 patients to receive
Study NCT04721015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-637
Description: Intravenous (IV) Infusion
Study NCT04721015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous (IV) Infusion
Study NCT04721015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral Tablets
Study NCT06008249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate 400 MG
Description: Lithium carbonate vs placebo (2:1)
Study NCT06008249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium Carbonate 400 MG
Description: Lithium carbonate vs placebo (2:1)
Study NCT05508672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)
Description: We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
Study NCT05508672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional smoking is harmful education
Description: In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians.
Study NCT04341623 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic interaction
Description: 10 patients to electronic surveys about moisturizer use
Study NCT04341623 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GPSkin
Description: Measuring moisture in the skin
Study NCT05447403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum combined with WeChat enhanced instructions
Description: Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
Study NCT06513455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome（60mg/m2）
Description: irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
Study NCT04827381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annotated Audio
Description: In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
Study NCT04827381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio
Description: In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
Study NCT04899765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
Study NCT04899765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
Study NCT04899765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT05766839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
Study NCT05738902 — intervention group
Intervention type: OTHER
Intervention: Assessment of compliance to ERAS.
Description: Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
Study NCT05249816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
Study NCT05249816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BBIBP-CorV vaccine
Description: BBIBP-CorV vaccine administered per manufacturer instructions.
Study NCT05849129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: High dose ascorbic acid delivered intravenously
Study NCT05849129 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% NaCl solution
Study NCT04609982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ear plugs
Description: giving half of the patients ear plugs
Study NCT05458739 — intervention group
Intervention type: DEVICE
Intervention: ClearCoast MR System
Description: The removed specimen is scanned using the ClearCoast MR System.
Study NCT05081830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic online intervention
Description: Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
Study NCT05081830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCC online intervention
Description: This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
Study NCT04824833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: local anesthetic application between serratus anterior muscle and 5th rib